Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,060.86 USD

1,060.86
452,590

+5.29 (0.50%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $1,065.30 +4.44 (0.42%) 9:12 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the Invesco Biotechnology & Genome (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD

by Zacks Equity Research

Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.

Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate

by Zacks Equity Research

Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca

by Zacks Equity Research

Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.

Sanghamitra Saha headshot

Oncology Market's Huge Potential Puts These Stocks in Focus

by Sanghamitra Saha

The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

by Zacks Equity Research

Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

by Zacks Equity Research

Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.

Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.

Regeneron's (REGN) Application for Blood Cancer Drug Accepted

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug

by Kinjel Shah

FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.

Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News

by Zacks Equity Research

Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.

Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies

by Zacks Equity Research

Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.

Bayer (BAYRY) Q2 Earnings Miss Estimates, '23 Outlook Lowered

by Zacks Equity Research

Bayer (BAYRY) misses earnings and sales estimates in the second quarter of 2023 due to lower volumes and decreased prices for glyphosate-based products. Management lowers its guidance.

Alnylam (ALNY) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.

Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.

Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.

Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.

Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the first half of 2023 was ordinary as COVID-19-test sales continue to decline and dent the top line.

Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB